Your browser is no longer supported. Please, upgrade your browser.
Settings
ASNS Arsanis, Inc. daily Stock Chart
ASNS [NASD]
Arsanis, Inc.
Index- P/E- EPS (ttm)-3.13 Insider Own20.19% Shs Outstand14.35M Perf Week-8.34%
Market Cap238.21M Forward P/E- EPS next Y-4.23 Insider Trans- Shs Float11.41M Perf Month-15.52%
Income-39.20M PEG- EPS next Q-1.04 Inst Own76.80% Short Float1.59% Perf Quarter-30.25%
Sales- P/S- EPS this Y-41.30% Inst Trans2.96% Short Ratio5.43 Perf Half Y42.73%
Book/sh3.39 P/B4.90 EPS next Y0.00% ROA-69.00% Target Price24.50 Perf Year-
Cash/sh4.46 P/C3.72 EPS next 5Y- ROE393.40% 52W Range10.40 - 28.69 Perf YTD30.09%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-41.80% Beta-
Dividend %- Quick Ratio7.40 Sales past 5Y- Gross Margin- 52W Low60.58% ATR1.48
Employees40 Current Ratio7.40 Sales Q/Q- Oper. Margin- RSI (14)46.99 Volatility8.88% 8.92%
OptionableNo Debt/Eq0.25 EPS Q/Q-49.20% Profit Margin- Rel Volume1.47 Prev Close16.60
ShortableYes LT Debt/Eq0.20 Earnings- Payout- Avg Volume33.33K Price16.70
Recom1.80 SMA20-2.06% SMA50-8.66% SMA200-0.10% Volume19,385 Change0.60%
Jun-14-18 08:00AM  Arsanis Out-Licenses Preclinical Stage Klebsiella pneumoniae Monoclonal Antibodies from ASN300 Program GlobeNewswire
Jun-05-18 07:50AM  Investor Expectations to Drive Momentum within Oxford Immunotec Global, Financial Engines, Brookfield Property Partners, Arsanis, QIWI, and Stitch Fix Discovering Underlying Factors of Influence GlobeNewswire
May-10-18 07:00AM  Arsanis Reports Business Highlights and Financial Results for First Quarter 2018 Business Wire
Apr-20-18 10:17AM  Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) PR Newswire
Apr-17-18 08:00AM  Arsanis to Present at the 28th European Congress of Clinical Microbiology and Infectious Diseases Business Wire +8.45%
Apr-09-18 07:40AM  Research Report Identifies Teck Resources, Adverum Biotechnologies, BeiGene, IPG Photonics, Arsanis, and G1 THERAPEUTICS with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Apr-04-18 08:00AM  Arsanis Out-Licenses Preclinical Stage E. coli Monoclonal Antibodies Business Wire +7.97%
Mar-20-18 08:00AM  Arsanis to Present at the Needham & Company 17th Annual Healthcare Conference Business Wire +9.37%
Mar-17-18 08:32AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Mar-15-18 08:10AM  Report: Exploring Fundamental Drivers Behind Mountain Province Diamonds, Limoneira, Arsanis, ExlService, Argo Group International, and Cellectis S.A. New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire +5.47%
Mar-14-18 08:00AM  Arsanis Granted Key Patents for ASN100 Covering Cross-Neutralizing S. aureus Toxin Antibodies Business Wire +5.98%
Mar-09-18 07:00AM  Arsanis Reports Financial Results and Highlights for Fourth Quarter and Full Year 2017 Business Wire
Mar-05-18 08:00AM  Arsanis to Present at the 38th Annual Cowen and Company Health Care Conference Business Wire
Dec-29-17 04:25PM  What You Must Know About Arsanis Incs (NASDAQ:ASNS) ROE Simply Wall St.
Nov-20-17 04:10PM  Arsanis Announces Closing of Initial Public Offering Business Wire
Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases. Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients. The company's preclinical pipeline comprises mAbs targeting various bacterial and viral pathogens, including respiratory syncytial virus. Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.